hydroxamic acid ester - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	hydroxamic acid ester	go back to main search page
Accession:	CHEBI:75606	browse the term
Definition:	A carboxamide that is a hydroxamic acid in which the hydrogen of the hydroxy group is replaced by an organyl group.
Synonyms:	related_synonym:	Formula=CHNO2R2; RC(O)NHOR'; RCONHOR'; SMILES=[]C(=O)NO[]; hydroxamate ester; hydroxamate esters; hydroxamic acid esters

show annotations for term's descendants Sort by:
Rat (153) Mouse (153) Human (155) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (153)

binimetinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

D-cycloserine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

Cycloserine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

DNA-damage inducible transcript 3

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

early growth response 1

increases expression

Cycloserine results in increased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

homer scaffold protein 1

multiple interactions

Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA]

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

mitogen activated protein kinase 1

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

poly (ADP-ribose) polymerase 1

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

PD 0325901

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetyl-CoA carboxylase alpha

multiple interactions

mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in increased expression of ACACA protein]]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

ADAM metallopeptidase domain 19

decreases expression
multiple interactions

mirdametinib results in decreased expression of ADAM19 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAM19 mRNA

NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ADAMTS6 mRNA

NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298

G

A-kinase anchoring protein 12

decreases expression

mirdametinib results in decreased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

[mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of AKT1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of AKT1 protein]; romidepsin inhibits the reaction [[mirdametinib co-treated with MK 2206] results in increased phosphorylation of AKT1 protein]
mirdametinib results in increased phosphorylation of AKT1 protein

PMID:22415236 PMID:25798061 PMID:27634878

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

decreases expression

mirdametinib results in decreased expression of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

ankyrin 3

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANK3 mRNA

NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300

G

anoctamin 1

decreases expression
multiple interactions

mirdametinib results in decreased expression of ANO1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ANO1 mRNA

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

alanyl aminopeptidase, membrane

decreases expression

mirdametinib results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

Rho GTPase activating protein 24

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ARHGAP24 mRNA

NCBI chr14:6,800,624...7,183,877
Ensembl chr14:6,800,631...7,183,823

G

ADP ribosylation factor like GTPase 4C

decreases expression

mirdametinib results in decreased expression of ARL4C mRNA

NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513

G

BCL2-antagonist/killer 1

increases expression
multiple interactions

mirdametinib results in increased expression of BAK1 protein
[mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BAK1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BAK1 protein

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

Bcl2-like 11

multiple interactions
increases expression

[mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of BCL2L11 protein; [romidepsin co-treated with mirdametinib] results in increased expression of BCL2L11 protein; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]

PMID:24576621 PMID:27634878

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

BH3 interacting domain death agonist

multiple interactions

[mirdametinib co-treated with MK 2206] results in increased expression of BID mRNA; [mirdametinib co-treated with MK 2206] results in increased expression of BID protein modified form

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

baculoviral IAP repeat-containing 3

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

C-C motif chemokine ligand 20

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CCL20 mRNA
mirdametinib results in decreased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

cyclin D1

multiple interactions

mirdametinib inhibits the reaction [camostat results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

multiple interactions

mirdametinib inhibits the reaction [camostat results in increased expression of CCND3 protein]

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

multiple interactions

mirdametinib inhibits the reaction [camostat results in increased expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

carnitine palmitoyltransferase 1c

multiple interactions

mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of CPT1C protein]]

NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342

G

C-X-C motif chemokine ligand 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
mirdametinib results in decreased expression of CXCL1 mRNA

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 3

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of CXCL1 mRNA
mirdametinib results in decreased expression of CXCL1 mRNA

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

cytochrome b5 reductase 2

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of CYB5R2 mRNA
mirdametinib results in decreased expression of CYB5R2 mRNA

NCBI chr 1:161,655,862...161,664,359
Ensembl chr 1:161,655,864...161,664,097

G

cytochrome P450, family 24, subfamily a, polypeptide 1

decreases expression
increases expression

mirdametinib results in decreased expression of CYP24A1 mRNA
mirdametinib results in increased expression of CYP24A1 mRNA

PMID:21976371 PMID:23872713

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 27, subfamily b, polypeptide 1

increases expression

mirdametinib results in increased expression of CYP27B1 mRNA

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression

mirdametinib results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

mirdametinib results in increased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

RIKEN cDNA D430041D05 gene like

decreases expression
multiple interactions

mirdametinib results in decreased expression of KIAA1549L mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of KIAA1549L mRNA

NCBI chr 3:90,506,559...90,782,427
Ensembl chr 3:90,510,942...90,781,894

G

discoidin, CUB and LCCL domain containing 2

decreases expression

mirdametinib results in decreased expression of DCBLD2 mRNA

NCBI chr11:42,125,525...42,179,927
Ensembl chr11:42,125,787...42,179,697

G

dynamin binding protein

decreases expression
multiple interactions

mirdametinib results in decreased expression of DNMBP mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DNMBP mRNA

NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604

G

dedicator of cytokinesis 4

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DOCK4 mRNA
mirdametinib results in decreased expression of DOCK4 mRNA

NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855

G

dual specificity phosphatase 4

decreases expression
multiple interactions

mirdametinib results in decreased expression of DUSP4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 6

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of DUSP6 mRNA
mirdametinib results in decreased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

ephrin A5

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EFNA5 mRNA

NCBI chr 9:102,316,753...102,595,480
Ensembl chr 9:102,320,295...102,597,413

G

early growth response 1

decreases expression
multiple interactions

mirdametinib results in decreased expression of EGR1 mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of EGR1 mRNA]

PMID:21976371 PMID:25104499

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

[Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

epithelial membrane protein 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of EMP1 mRNA
mirdametinib results in decreased expression of EMP1 mRNA

NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
decreases expression

mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 mRNA]; mirdametinib inhibits the reaction [Cisplatin results in increased expression of ERCC1 protein]
mirdametinib results in decreased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

ERCC excision repair 4, endonuclease catalytic subunit

increases expression

mirdametinib results in increased expression of ERCC4 mRNA

NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369

G

endothelial cell-specific molecule 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ESM1 mRNA
mirdametinib results in decreased expression of ESM1 mRNA

NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804

G

ETS proto-oncogene 1, transcription factor

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

ETS variant transcription factor 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV1 mRNA
mirdametinib results in decreased expression of ETV1 mRNA

NCBI chr 6:55,590,149...55,681,784
Ensembl chr 6:55,590,234...55,681,775

G

ETS variant transcription factor 4

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV4 mRNA
mirdametinib results in decreased expression of ETV4 mRNA

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

ETS variant transcription factor 5

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ETV5 mRNA
mirdametinib results in decreased expression of ETV5 mRNA

NCBI chr11:78,608,618...78,666,221
Ensembl chr11:78,608,710...78,666,215

G

fatty acid synthase

multiple interactions

mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 23

multiple interactions

mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; mirdametinib results in increased expression of and results in increased secretion of FGF23 protein

NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821

G

formin-like 2

decreases expression

mirdametinib results in decreased expression of FMNL2 mRNA

NCBI chr 3:37,348,791...37,624,746
Ensembl chr 3:37,348,574...37,624,754

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression
multiple interactions

mirdametinib results in decreased expression of FOS mRNA
mirdametinib inhibits the reaction [camostat results in increased expression of FOS mRNA]

PMID:21976371 PMID:25104499

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

decreases expression
multiple interactions

mirdametinib results in decreased expression of FOSL1 protein
[mirdametinib co-treated with silmitasertib] results in decreased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box G1

decreases expression
multiple interactions

mirdametinib results in decreased expression of FOXG1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of FOXG1 mRNA

NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607

G

forkhead box O3

increases expression
multiple interactions

mirdametinib results in increased expression of FOXO3 protein
mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of FOXO3 protein]; mirdametinib promotes the reaction [Luteolin results in increased expression of FOXO3 protein]

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

glutaredoxin

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GLRX mRNA
mirdametinib results in decreased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glycophorin C

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of GYPC mRNA
mirdametinib results in decreased expression of GYPC mRNA

NCBI chr18:24,160,738...24,193,408
Ensembl chr18:24,160,739...24,193,204

G

hyaluronan synthase 2

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HAS2 mRNA
mirdametinib results in decreased expression of HAS2 mRNA

NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933

G

histone deacetylase 9

decreases expression
multiple interactions

mirdametinib results in decreased expression of HDAC9 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HDAC9 mRNA

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

hydroxysteroid (17-beta) dehydrogenase 2

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of HSD17B2 mRNA
mirdametinib results in decreased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

heat shock transcription factor 1

decreases activity

mirdametinib results in decreased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

5-hydroxytryptamine receptor 7

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of HTR7 mRNA
mirdametinib results in decreased expression of HTR7 mRNA

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

interferon gamma

multiple interactions

mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 3

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

interleukin 15

multiple interactions

mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL15 protein results in increased secretion of IFNG protein]

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 18

multiple interactions

mirdametinib inhibits the reaction [[IL15 protein co-treated with IL18 protein] results in increased secretion of IFNG protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of IL1B mRNA
mirdametinib results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor accessory protein-like 1

decreases expression
multiple interactions

mirdametinib results in decreased expression of IL1RAPL1 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of IL1RAPL1 mRNA

NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772

G

interleukin 2

multiple interactions

mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased secretion of IFNG protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

inhibin subunit beta A

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of INHBA mRNA

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

integrin subunit alpha 2

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ITGA2 mRNA
mirdametinib results in decreased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit beta like 1

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of ITGBL1 mRNA
mirdametinib results in decreased expression of ITGBL1 mRNA

NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

mirdametinib results in decreased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kinesin family member 24

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIF24 mRNA
mirdametinib results in decreased expression of KIF24 mRNA

NCBI chr 5:56,561,019...56,628,040
Ensembl chr 5:56,561,154...56,628,025

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of KIT mRNA
mirdametinib results in decreased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

killer cell lectin like receptor K1

multiple interactions

mirdametinib inhibits the reaction [IL15 protein results in increased expression of KLRK1 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of KLRK1 protein]

NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459

G

KRAS proto-oncogene, GTPase

multiple interactions

KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in increased expression of BCL2L11 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in increased expression of BCL2L11 protein]]; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; KRAS protein affects the susceptibility to [mirdametinib co-treated with NVP-BKM120]
[mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]

NCBI chr 4:178,185,418...178,218,484

G

lipoprotein lipase

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leupaxin

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of LPXN mRNA
mirdametinib results in decreased expression of LPXN mRNA

NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

mirdametinib inhibits the reaction [Luteolin results in increased expression of and results in increased lipidation of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen activated protein kinase kinase 1

multiple interactions

mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAP2K1 protein]]

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase kinase 2

multiple interactions

mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAP2K2 protein]]

NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK1 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK1 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [NVP-BKM120 inhibits the reaction [mirdametinib results in increased phosphorylation of MAPK1 protein]]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK1 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAPK1 protein]]

PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; [mirdametinib co-treated with silmitasertib] results in decreased phosphorylation of MAPK3 protein; [MK 2206 co-treated with mirdametinib] results in decreased phosphorylation of MAPK3 protein; dactolisib promotes the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; KRAS protein affects the reaction [mirdametinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; mirdametinib inhibits the reaction [Luteolin results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [NVP-BKM120 results in increased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Axitinib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [pazopanib results in decreased phosphorylation of MAPK3 protein]; mirdametinib promotes the reaction [Sunitinib results in decreased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [camostat results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein]
mirdametinib inhibits the reaction [FGF23 protein results in increased phosphorylation of MAPK3 protein]; mirdametinib inhibits the reaction [polyphyllin I inhibits the reaction [Dietary Fats results in decreased expression of MAPK3 protein]]

PMID:21996734 PMID:22415236 PMID:23872713 PMID:24011934 PMID:24576621 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
decreases expression
increases expression

[mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib co-treated with MK 2206] results in increased expression of MCL1 protein; [romidepsin co-treated with mirdametinib] results in increased expression of MCL1 protein; KRAS protein affects the reaction [mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]]; KRAS protein affects the reaction [mirdametinib results in decreased expression of MCL1 protein]; KRAS protein affects the reaction [NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased expression of MCL1 protein]; NVP-BKM120 promotes the reaction [mirdametinib results in decreased expression of MCL1 protein]
mirdametinib results in increased expression of MCL1 protein

PMID:24576621 PMID:27634878

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

monoglyceride lipase

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of MGLL mRNA
mirdametinib results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

marker of proliferation Ki-67

multiple interactions

[mirdametinib affects the susceptibility to KRAS protein] affects the reaction [NVP-BKM120 results in decreased expression of MKI67 protein]; mirdametinib inhibits the reaction [camostat results in increased expression of MKI67 protein]

PMID:24576621 PMID:25104499

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

monocyte to macrophage differentiation-associated

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMD mRNA
mirdametinib results in decreased expression of MMD mRNA

NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528

G

matrix metallopeptidase 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP1 mRNA
mirdametinib results in decreased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 10

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

mechanistic target of rapamycin kinase

multiple interactions

mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [MTOR gene mutant form results in increased phosphorylation of MAPK3 protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

(+)-JQ1 compound promotes the reaction [mirdametinib results in decreased expression of MYC protein]; mirdametinib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

neuron navigator 3

decreases expression
multiple interactions

mirdametinib results in decreased expression of NAV3 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NAV3 mRNA

NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698

G

natural cytotoxicity triggering receptor 3

multiple interactions

mirdametinib inhibits the reaction [IL15 protein results in increased expression of NCR3 protein]; mirdametinib inhibits the reaction [IL2 protein results in increased expression of NCR3 protein]

NCBI chr20:3,637,242...3,643,748
Ensembl chr20:3,638,240...3,643,799

G

neurofibromin 1

multiple interactions

NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]]

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

NME/NM23 family member 5

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NME5 mRNA

NCBI chr18:26,163,558...26,180,742
Ensembl chr18:26,163,555...26,180,794

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

mirdametinib results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

neuronal cell adhesion molecule

decreases expression

mirdametinib results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

neuropilin 1

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of NRP1 mRNA
mirdametinib results in decreased expression of NRP1 mRNA

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

neurotrimin

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of NTM mRNA
mirdametinib results in decreased expression of NTM mRNA

NCBI chr 8:27,376,582...28,366,604
Ensembl chr 8:27,377,773...28,366,595

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

[mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein; [mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein; KRAS protein affects the susceptibility to [[mirdametinib co-treated with NVP-BKM120] results in increased cleavage of PARP1 protein]; mirdametinib promotes the reaction [Luteolin results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [[mirdametinib co-treated with MK 2206] results in increased cleavage of PARP1 protein]; romidepsin promotes the reaction [mirdametinib results in increased cleavage of PARP1 protein]

PMID:24576621 PMID:27634878 PMID:32268164

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

multiple interactions

mirdametinib inhibits the reaction [camostat results in increased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

programmed cell death 1 ligand 2

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PDCD1LG2 mRNA

NCBI chr 1:227,158,941...227,223,938
Ensembl chr 1:227,158,941...227,223,938

G

paternally expressed 3

decreases expression

mirdametinib results in decreased expression of PEG3 mRNA

NCBI chr 1:67,097,874...67,124,692
Ensembl chr 1:67,097,904...67,124,671

G

plasminogen activator, urokinase

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAU mRNA
mirdametinib results in decreased expression of PLAU mRNA

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

plasminogen activator, urokinase receptor

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PLAUR mRNA
mirdametinib results in decreased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

peroxisome proliferator-activated receptor gamma

multiple interactions

mirdametinib inhibits the reaction [Protein Kinase Inhibitors results in increased phosphorylation of and results in decreased activity of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PR/SET domain 1

decreases expression
multiple interactions

mirdametinib results in decreased expression of PRDM1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRDM1 mRNA

NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488

G

paired related homeobox 1

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of PRRX1 mRNA
mirdametinib results in decreased expression of PRRX1 mRNA

NCBI chr13:75,600,777...75,671,896
Ensembl chr13:75,601,706...75,670,866

G

pentraxin 3

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of PTX3 mRNA
mirdametinib results in decreased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

Rac family small GTPase 1

affects response to substance

RAC1 protein alternative form affects the susceptibility to mirdametinib

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

reelin

decreases expression
multiple interactions

mirdametinib results in decreased expression of RELN mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of RELN mRNA

NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211

G

ribosomal protein S6

multiple interactions
decreases phosphorylation

2-amino-8-(4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido(2,3-d)pyrimidin-7(8H)-one promotes the reaction [mirdametinib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [dactolisib results in decreased phosphorylation of RPS6 protein]; mirdametinib promotes the reaction [NVP-BKM120 results in decreased phosphorylation of RPS6 protein]

PMID:22415236 PMID:24011934 PMID:24576621

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

secretogranin V

multiple interactions

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SCG5 mRNA

NCBI chr 3:100,544,101...100,588,558
Ensembl chr 3:100,544,099...100,588,463

G

semaphorin 3A

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SEMA3A mRNA
mirdametinib results in decreased expression of SEMA3A mRNA

NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432

G

sialic acid binding Ig-like lectin 15

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of SIGLEC15 mRNA
mirdametinib results in decreased expression of SIGLEC15 mRNA

NCBI chr18:71,506,416...71,521,894
Ensembl chr18:71,505,399...71,521,881

G

solute carrier family 6 member 15

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLC6A15 mRNA
mirdametinib results in decreased expression of SLC6A15 mRNA

NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239

G

slit guidance ligand 2

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SLIT2 mRNA
mirdametinib results in decreased expression of SLIT2 mRNA

NCBI chr14:62,616,337...62,955,934
Ensembl chr14:62,617,067...62,955,948

G

SRY-box transcription factor 9

decreases expression

mirdametinib results in decreased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

secreted phosphoprotein 1

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPP1 mRNA

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sprouty RTK signaling antagonist 2

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of SPRY2 mRNA
mirdametinib results in decreased expression of SPRY2 mRNA

NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ST3GAL6 mRNA
mirdametinib results in decreased expression of ST3GAL6 mRNA

NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776

G

stanniocalcin 1

decreases expression
multiple interactions

mirdametinib results in decreased expression of STC1 mRNA
[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of STC1 mRNA

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

syntaxin 1A

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of STX1A mRNA
mirdametinib results in decreased expression of STX1A mRNA

NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930

G

SUZ12 polycomb repressive complex 2 subunit

multiple interactions

NF1 protein inhibits the reaction [SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]]; SUZ12 gene mutant form results in increased susceptibility to [(+)-JQ1 compound co-treated with mirdametinib]

NCBI chr10:64,967,035...65,012,916
Ensembl chr10:64,966,967...65,012,738

G

synaptic Ras GTPase activating protein 1

affects response to substance

SYNGAP1 protein affects the susceptibility to mirdametinib

NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672

G

T-box transcription factor 3

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TBX3 mRNA
mirdametinib results in decreased expression of TBX3 mRNA

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

tissue factor pathway inhibitor

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TFPI mRNA
mirdametinib results in decreased expression of TFPI mRNA

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

transglutaminase 2

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TGM2 mRNA
mirdametinib results in decreased expression of TGM2 mRNA

NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981

G

toll-like receptor 4

decreases expression
multiple interactions

mirdametinib results in decreased expression of TLR4 mRNA
[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane protein 156

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TMEM156 mRNA
mirdametinib results in decreased expression of TMEM156 mRNA

NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449

G

TNF superfamily member 15

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of TNFSF15 mRNA
mirdametinib results in decreased expression of TNFSF15 mRNA

NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:77,139,878...77,156,228

G

tumor protein p53

multiple interactions

[mirdametinib co-treated with MK 2206] results in increased expression of and results in increased phosphorylation of TRP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tribbles pseudokinase 2

multiple interactions
decreases expression

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of TRIB2 mRNA
mirdametinib results in decreased expression of TRIB2 mRNA

NCBI chr 6:38,545,971...38,570,349
Ensembl chr 6:38,545,975...38,569,370

G

uncoupling protein 1

multiple interactions

mirdametinib inhibits the reaction [Protein Kinase Inhibitors inhibits the reaction [FASN protein results in increased expression of UCP1 protein]]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

UDP glycosyltransferase 8

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of UGT8 mRNA

NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:214,264,483...214,332,660

G

vascular endothelial growth factor C

multiple interactions
decreases expression

[(+)-JQ1 compound co-treated with mirdametinib] results in decreased expression of VEGFC mRNA
mirdametinib results in decreased expression of VEGFC mRNA

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

G

zinc finger E-box binding homeobox 1

multiple interactions

[mirdametinib co-treated with (+)-JQ1 compound] results in decreased expression of ZEB1 mRNA

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

selumetinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 11

increases expression

AZD 6244 results in increased expression of BCL2L11 protein

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

cathelicidin antimicrobial peptide

multiple interactions

AZD 6244 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; AZD 6244 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]]

NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543

G

caspase 3

multiple interactions
increases cleavage

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]
AZD 6244 results in increased cleavage of CASP3 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP3 protein]

PMID:17876044 PMID:27222248

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases cleavage
multiple interactions

AZD 6244 results in increased cleavage of CASP7 protein
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

multiple interactions

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

cyclin B1

decreases expression
multiple interactions

AZD 6244 results in decreased expression of CCNB1 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CCNB1 protein]

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

multiple interactions

AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of and results in decreased phosphorylation of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin dependent kinase 2

multiple interactions
decreases expression

Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK2 protein]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression
multiple interactions

AZD 6244 results in decreased expression of CDK4 protein
Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of CDK4 protein]

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

AZD 6244 promotes the reaction [decitabine results in increased expression of CDKN1A]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

chromodomain helicase DNA binding protein 4

multiple interactions

AZD 6244 inhibits the reaction [Harmine results in increased phosphorylation of CHD4 protein]

NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541

G

cAMP responsive element binding protein 1

decreases phosphorylation

AZD 6244 results in decreased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

[Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases phosphorylation

AZD 6244 results in decreased phosphorylation of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

Janus kinase 2

increases phosphorylation

selumetinib increases phosphorylation of JAK2 protein in colonic epithelium

RGD

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

KRAS proto-oncogene, GTPase

multiple interactions

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]

NCBI chr 4:178,185,418...178,218,484

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]
AZD 6244 results in decreased phosphorylation of MAPK1 protein
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK1 protein]

PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]
AZD 6244 results in decreased phosphorylation of MAPK3 protein
AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of and results in decreased activity of MAPK3 protein]

PMID:17876044 PMID:22415236 PMID:27222248 PMID:31790661

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

decreases activity

AZD 6244 results in decreased activity of MMP1 protein

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 2

decreases activity

AZD 6244 results in decreased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

decreases activity

AZD 6244 results in decreased activity of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

Doxorubicin promotes the reaction [AZD 6244 results in decreased expression of MYC protein]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

AZD 6244 results in increased cleavage of PARP1 protein
AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]
Doxorubicin promotes the reaction [AZD 6244 results in increased cleavage of PARP1 protein]

PMID:17876044 PMID:27222248

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

ribosomal protein S6 kinase A1

multiple interactions
decreases phosphorylation

Doxorubicin promotes the reaction [AZD 6244 results in decreased phosphorylation of RPS6KA1 protein]

NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272

G

suppressor of cytokine signaling 3

multiple interactions

AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 mRNA]; AZD 6244 inhibits the reaction [flavone results in increased expression of SOCS3 protein]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

uncoupling protein 1

multiple interactions

AZD 6244 inhibits the reaction [Harmine results in increased expression of UCP1 mRNA]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19932
chemical entity	19930
atom	19930
nonmetal atom	19859
nitrogen atom	19024
nitrogen molecular entity	19024
organonitrogen compound	18871
carboxamide	17579
hydroxamic acid ester	153
4-amino-1,2-oxazolidin-3-one +	8
Furmecyclox	0
GDC-0623	0
PD 0325901	134
binimetinib	1
selumetinib	26
Path 2
Term	Annotations
CHEBI ontology	19932
subatomic particle	19930
composite particle	19930
hadron	19930
baryon	19930
nucleon	19930
atomic nucleus	19930
atom	19930
main group element atom	19876
p-block element atom	19876
carbon group element atom	19816
carbon atom	19812
organic molecular entity	19812
heteroorganic entity	19559
organochalcogen compound	19317
organooxygen compound	19231
carbon oxoacid	18687
carboxylic acid	18684
carboacyl group	17725
univalent carboacyl group	17725
carbamoyl group	17579
carboxamide	17579
hydroxamic acid	6338
hydroxamic acid ester	153
4-amino-1,2-oxazolidin-3-one +	8
Furmecyclox	0
GDC-0623	0
PD 0325901	134
binimetinib	1
selumetinib	26

paths to the root